The US National Institute of Mental Health supported an initiative to facilitate the development of pharmacological agents for enhancing neurocognition in patients with schizophrenia. This has been accomplished through a consensus-building process that has included representatives from academia, the pharmaceutical industry, and government. The group has addressed obstacles to drug development that include (i) the lack of a well-accepted instrument for measuring neurocognition in clinical trials; (ii) the lack of a consensus on the best molecular target or targets for drug development; (iii) the lack of a consensus regarding the optimal trial design for either comedication that improves cognition when added to an antipsychotic or a broad spectrum agent that improves cognition and treats psychosis; and (iv) the approaches of regulatory agencies such as the US Food and Drug Administration to approving and labeling a new agent.
ing periods of remission. In addition, first-and secondgeneration antipsychotics are relatively ineffective at treating these symptoms. Patients treated with these agents tend to have continuing deficits even when adequately treated with antipsychotics. 5 Further, the neurocognitive deficits tend to be relatively severe. A metaanalysis by Heinrichs and Zakzanis 6 demonstrates that the impairments in schizophrenia are particularly severe for memory, attention, and executive function. In these areas, individuals with schizophrenia-on average-performed 1.5 standard deviations below community norms. The most important reason for the focus on neurocognition may be that these impairments appear to be related to the functional outcomes of patients. A review by Green 7 found that the impairments in social and vocational functioning in schizophrenia were strongly related to the impairments in neurocognition. The magnitudes for the relationships between cognitive deficits and functional outcome are medium for individual cognitive constructs such as attention or working memory, but the relationships can be strong when summary scores (eg, composites of several cognitive functions) are used. [8] [9] [10] This literature on cognitive linkages to functional outcome provides a compelling rationale for intervention development at the level of cognition. In contrast to cognitive deficits, clinical symptoms are only weakly related to functional outcome in schizophrenia.
Facilitating drug development
Hyman and Fenton 2 have suggested a strategy for drug development that focuses on dissecting psychiatric disorders into component dimensions of psychopathology that may be more closely related to pathophysiological processes. These components rather than the illnesses themselves may be more amenable to novel pharmacological approaches to therapeutics. This strategy encourages the development of new therapeutics for schizophrenia that move beyond positive symptoms as clinical targets to focus on dimensions of the illness most associated with functional disability. The goal of the MATRICS initiative is to address important obstacles that are likely to interfere with the development of new pharmacological approaches to improving neurocognition in schizophrenia. These obstacles include (i) the lack of a well-accepted instrument for measuring neurocognition in clinical trials; (ii) the lack of a consensus on the best molecular target or targets for drug development; (iii) the lack of a consensus regarding the optimal trial design for either comedication that improves cognition when added to an antipsychotic or a broad-spectrum agent that improves cognition and treats psychosis; and (iv) the approaches of regulatory agencies such as the US Food and Drug Administration (FDA) to approving and labeling a new agent. The MATRICS group has attempted to address each of these obstacles.
Development of the MATRICS battery
The selection of the MATRICS battery emerged from a 2-year process that involved a broad range of individuals from academia, industry, and government. The process began with a process for determining the domains of neurocognition that would be evaluated as well as the criteria for selecting tests for each domain. The domains emerged from both factor analysis of existing databases and expert opinion. 11 Expert opinion was used to prioritize the criteria for test selection. Table I lists the criteria for test selection. Approximately 90 tests were proposed for measuring performance in the eight domains. The characteristics of each test were evaluated and candidates were narrowed to 36. These tests were graded according to the criteria in Table I and further narrowed to one or two tests in each domain. These tests were then evaluated in a fivesite MATRICS Psychometrics and Standardization Study. The tests were compared with one another in a diverse group of patients with schizophrenia. The results led to the final selection of the battery, which is listed in Table II. C l i n i c a l r e s e a r c h 110 Table I . Essential criteria for a consensus cognitive battery for clinical trials in schizophrenia.
• Valid assessment of cognition at the level of all individual major cognitive domains • Inclusion of the following cognitive domains: speed of processing, attention/vigilance, working memory, verbal learning and memory, visual learning and memory, reasoning and problem solving, and social cognition • High test-retest reliability • High utility as a repeated measure • Demonstrated relationship to functional outcome • Demonstrated tolerability and practicality
Co-primary measures
At one of the MATRICS meetings, Thomas Laughren from the FDA confirmed that cognition in schizophrenia was a reasonable clinical target, but that his agency was unlikely to approve a drug based only on improvement on a neuropsychological test. Approval would require an outcome with greater face validity, though it would not be necessary to demonstrate that a drug actually improved patient functioning. He did agree that reasonable coprimary measures would be functional capacity measures or proxy measures that demonstrate an individual's ability to perform a task, and not whether they actually do it or a patient or caregiver's interview-based assessment of cognition. With this in mind, we evaluated a number of potential measures of functional capacity and interview-based measures of cognition in the psychometric study. One instrument was selected to represent each domain: the Social Functioning Scale (SFS), 12 the SCORS (R. Keefe, personal communication), the Maryland Assessment of Social Competence (MASC), 13 and the UCSD PerformanceBased Skills Assessment (UPSA).
14 The Clinical Global Impression (CGI)-Cogs (Bilder et al, personal communication) was added at a later time as an alternative interview-based measure. These measures were administered along with the MATRICS battery in the psychometric study and evaluated using similar criteria for the selection neuropsychological tests. The results indicated that all of the measures had reasonable psychometric properties. In addition, the measures had modest relationships with functioning and strong relationships with cognition.
Trial design
An FDA-MATRICS consensus meeting on trial design brought together a group of neuropsychologists, clinical trialists, industry representatives, and representatives from the NIMH and the FDA. The meeting included a wide-ranging discussion of issues including subject selection, statistical issues, and design issues. The meeting focused on issues that should be addressed for either a comedication that would be added to an antipsychotic or a broad-spectrum antipsychotic that would be effective for psychotic symptoms and at enhancing cognition. The consensus recommendations are published in a special article by Robert Buchanan in Schizophrenia Bulletin. 15 Here are some of the recommendations: • Include subjects who are clinically stable.
• Exclude subjects only if impairment compromises test validity or if they perform at ceiling. • For comedication, compare addition of drug or placebo to current antipsychotic.
• For a broad-spectrum antipsychotic, compare experimental drug to an antipsychotic that does not impair cognition.
• Monitor outcome with MATRICS battery and a coprimary measure of functional capacity or interview-based cognitive assessment.
Molecular targets
We also developed a process to develop a consensus regarding the molecular targets that should be a focus of drug development. This was carried out under the lead- 
